Today: 11 Fevereiro 2026
Subscribe
Search result

Phantom 4 RTK/feed/category/dji-mavic-3-pl- Page 272

QuantumScape (QS) Stock Soars 200% on EV Battery Breakthroughs – What’s Next for This High-Voltage Bet?

QuantumScape (QS) Stock Soars 200% on EV Battery Breakthroughs – What’s Next for This High-Voltage Bet?

QuantumScape shares have surged about 180% in 2025, hitting nearly $19 before settling near $17 in late October. Q3 results showed a net loss of $0.18 per share, no product revenue, but $12.8 million in customer billings and $1 billion in liquidity. Major partnerships were signed with Corning and Murata, and Volkswagen advanced $260 million in royalties. Most analysts remain cautious, with consensus targets well below current prices.
31 Outubro 2025
Astera Labs Stock Skyrockets on AI Buzz and Photonics Deal – Can ALAB Keep Climbing?

Astera Labs Stock Skyrockets on AI Buzz and Photonics Deal – Can ALAB Keep Climbing?

Astera Labs shares surged over 12% to $191 intraday on Oct. 31, 2025, though still below their September high of $262.90. The stock rebounded after a volatile month that included a 19% drop on Oct. 15 and the Oct. 22 acquisition of aiXscale Photonics. Q2 revenue jumped 150% year-over-year to $191.9 million, beating estimates. Institutional investors hold about 60% of shares, while insiders sold over $190 million in August.
31 Outubro 2025
··
Adtalem (ATGE) Stock Plummets 27% After Earnings – Latest News, Key Facts & Expert Outlook

Adtalem (ATGE) Stock Plummets 27% After Earnings – Latest News, Key Facts & Expert Outlook

Adtalem Global Education posted Q1 adjusted EPS of $1.75, up 35.7% year-over-year, on $462.3 million revenue, beating estimates. Shares plunged 27% to $102 after the report, despite reaffirmed guidance and strong results. Insider selling, including a director’s 25,500-share sale, weighed on sentiment. Market cap now stands near $3.7 billion; analysts remain mostly bullish with a $146 average target.
31 Outubro 2025
··
Virgin Galactic’s Wild 2025 Ride: Space Tourism Liftoff, Stock Surges & Cash Burn – What’s Next for SPCE?

Virgin Galactic’s Wild 2025 Ride: Space Tourism Liftoff, Stock Surges & Cash Burn – What’s Next for SPCE?

Virgin Galactic shares surged over 40% in October 2025 before dropping back, closing at $3.94 on Oct. 31, down about 40% year-to-date and 99% below their 2021 peak. The company paused commercial flights after June 2024 and is burning $100–125 million per quarter, with about 18 months of cash left. Wall Street targets hover near $4, with some analysts warning of further downside.
1 Novembro 2025
··
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 Novembro 2025
AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital shares surged 224% to a $5.47 intraday high on Oct. 31, 2025, before closing up 75% at $2.95, with trading volume topping 323 million shares. The company reported a 1,085.9% year-over-year revenue jump to $73.2 million for the half-year ended April 2025, driven by its TGE acquisition. Net profit hit $51.5 million, but most gains came from one-off investment income. HKD now trades near $3.00.
3 Novembro 2025
IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories reported Q3 2025 revenue of $1.11 billion, up 13%, and EPS of $3.40, up 21%, beating expectations and raising full-year guidance. Shares have surged about 50–55% year-to-date, trading near all-time highs. The company holds nearly half the global veterinary diagnostics market and generates about 79% of sales from recurring revenue. Institutional ownership stands at approximately 94%.
3 Novembro 2025
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 Novembro 2025
·
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Technologies shares surged 1,300% from June lows, averting Nasdaq delisting and prompting the company to cancel a planned reverse split. Despite the rally, Opendoor posted a $29 million Q2 loss and expects Q3 revenue to fall sharply. The company named Kaz Nejatian CEO in September, shifting focus to AI-powered real estate. Wall Street analysts remain skeptical, with price targets below current levels.
3 Novembro 2025
·
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB named Chirantan “CJ” Desai as its next CEO, replacing Dev Ittycheria, who will step down in November 2025 after 11 years. Shares jumped about 9% in pre-market trading, nearing all-time highs, as the company raised its Q3 FY2026 outlook and analysts boosted price targets. Ittycheria will stay on as an advisor during the transition. Final Q3 results are due December 1, 2025.
3 Novembro 2025
··
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 Novembro 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 Novembro 2025
·
Palantir’s $500 Billion AI Surge: Record Earnings, Stock Whiplash & What’s Next for PLTR

Palantir’s $500 Billion AI Surge: Record Earnings, Stock Whiplash & What’s Next for PLTR

Palantir’s Q3 2025 revenue surged 63% year-over-year to $1.18 billion, with adjusted EPS of $0.21, beating estimates and raising full-year guidance to $4.4 billion. Shares hit a record near $220 before dropping 4% as investors took profits. U.S. commercial revenue more than doubled, now surpassing government sales. The stock remains volatile, with analysts split over its high valuation.
4 Novembro 2025
··
Lenskart IPO Frenzy: Sky-High Valuation Meets Surging Demand – Will Investors See Big Gains?

Lenskart IPO Frenzy: 7x Oversubscribed Amid Grey Market Jitters – Is Groww’s IPO the Safer Bet?

Lenskart’s ₹7,278 crore IPO was subscribed about 7 times, led by non-institutional bids at 10.2×. Shares list November 10, with grey market premiums cooling to ~14% above the ₹402 issue price. The IPO values Lenskart near ₹70,000 crore, or ~235× FY25 earnings, sparking debate over rich pricing. Brokerages mostly recommend subscribing, but some experts warn of stretched valuations and possible correction.
4 Novembro 2025
Bitcoin Miner to AI Cloud Sensation: Why Iris Energy (IREN) Stock Is Soaring in 2025

From Bitcoin Miner to AI Cloud Powerhouse: Iris Energy’s Meteoric Rise (IREN Stock Soars on $9.7B Microsoft Deal)

Iris Energy (IREN) closed at $67.75 on Nov. 3, 2025, after announcing a $9.7 billion, five-year AI cloud contract with Microsoft, sending shares up 11.5%. The company’s market cap now tops $16.5 billion, up from $1 billion at the start of 2025. IREN posted FY2025 revenue of $501 million and net income of $86.9 million, driven by its pivot to AI cloud services and continued Bitcoin mining.
4 Novembro 2025
···
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark shares plunged 14.6% on Nov. 3 to a 52-week low near $102 after announcing a $40 billion cash-and-stock deal to acquire Kenvue at a 46% premium. The drop erased about 15% of KMB’s market value, with the stock now down 21% year-over-year. Investors cited concerns over Kenvue’s litigation risks and debt load. KMB trades at 17.3× earnings, with a 4.9% dividend yield.
4 Novembro 2025
··
1 … 270 271 272 273 274 … 277
Go toTop